QIAGEN Launches New Automated Modular Testing P...

Qiagen N.V. / QIAGEN Launches New Automated Modular Testing Platform for Molecular Diagnostics processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. 

QIAsymphony RGQ System scores with highest possible flexibility and the broadest
                   available range of PCR-based test systems

Hilden,  Germany, and Germantown, MD.,  September 1, 2010 - QIAGEN N.V. (NASDAQ:
QGEN;  Frankfurt Prime Standard:  QIA) today launched  its novel QIAsymphony RGQ
system.  The automated  platform has  been specifically  designed to address the
fast-growing  molecular  diagnostics  market,  particularly  for applications in
"Profiling"  and "Personalized Healthcare"*. It is  the only modular system that
covers  entire laboratory workflows  from the initial  sample preparation to the
final   result.   The  QIAsymphony  RGQ  thereby  provides  its  users  with  an
unprecedented  level of flexibility: Customers can use the new platform not only
to  run several existing QIAGEN tests, but also to develop and conduct their own
PCR-based assays.

The QIAsymphony RGQ system is approved for in-vitro diagnostic use in Europe and
launches  with several molecular assays for the detection of viruses such as HIV
and  Hepatitis, as well  as a specific  test panel for transplantation medicine.
All  of  these  products  from  QIAGEN's  artus  product range have been already
validated  for clinical use  in connection with  the new system.* Numerous other
products will complement the existing test portfolio over the next months. These
products  will  include  tests  for  biomarkers  such  as  KRAS, EGFR or PI3K in
personalized  healthcare  applications,  assays  for  the detection of influenza
viruses, as well as a dedicated women's health panel. This will allow diagnostic
and  research  access  to  the  broadest  commercially available PCR-based assay
portfolio in the marketplace.

The  system also allows customers to run custom laboratory developed tests (LDT)
which  can be validated  for clinical use.  In molecular diagnostics, laboratory
developed tests account for about 40 percent of the global market volume and for
an   even  higher  share  of  all  existing  test  parameters.  Facing  stricter
requirements   from   regulatory   bodies   such  as  the  U.S.  Food  and  Drug
Administration   (FDA),  this  sector  shows  signs  of  a  growing  demand  for
standardized  and  clinically  proven  systems  for  the  development  of custom
PCR-based  assays. With the QIAsymphony RGQ,  developers and users of such tests
gain  access  to  instruments  and  reagents  that match the highest quality and
functionality  standards for clinical applications. To date, there are more than
200 such applications that are compatible with the new QIAsymphony RGQ platform.

"The  launch of  our QIAsymphony  RGQ is  a very  important milestone in further
expanding  our  leading  position  in  molecular diagnostics", said Peer Schatz,
QIAGEN's  CEO. "The  integrated and  validated system  was designed to meet both
current  and  future  needs  of  molecular  diagnostic labs. We will continue to
complement  the system not  only by expanding  the existing assay portfolio, but
also by adding further unique performance features." Future expansions that have
been   already   announced  by  the  company  include  the  integration  of  the
Pyrosequencing  detection  technology  and  the  capability  to  detect multiple
molecular targets in a single test run, known as Multiplexing.

With  an increase of 14 percent, QIAGEN's  automation business has seen a strong
revenue  growth in the second quarter of 2010. Instrument sales thereby also add
to  long-term reagent and consumable sales,  which account for 85 percent of the
company's  business.  QIAGEN  has  already  registered  a  significant amount of
pre-orders for the QIAsymphony RGQ system.

The QIAsymphony RGQ is composed of three modules: the award winning "QIAsymphony
SP"  for  sample  preparation,  the  new  "QIAsymphony  AS" for assay setup, and
QIAGEN's  real-time PCR  detection platform  "Rotor-Gene Q".  Two of  its unique
features  include continuous  sample loading  and the  ability to  run different
tests  for  each  sample.  These  features  address  a  critical  requirement in
"Profiling"  and  "Personalized  Healthcare"  applications,  where  laboratories
typically  process a variety  of different samples  such as blood  or tissue and
have to test them for different molecular targets.

More  information  about  QIAsymphony  RGQ  is  available  on  QIAGEN's European
websites at 

http://www.qiagen.com/mc/QIAsymphonyRGQ.

*  The  tests  are  currently  not  available  in the United States for in-vitro
diagnostic  use. They have not been cleared or approved by authorities including
the United States Food and Drug Administration or any other regulatory agency in
the United States for human diagnostic or other clinical use.

About QIAGEN
QIAGEN N.V., a Netherlands holding company, is the leading global provider of
sample and assay technologies. Sample technologies are used to isolate and
process DNA, RNA and proteins from biological samples such as blood or tissue.
Assay technologies are used to make such isolated bio-molecules visible. QIAGEN
has developed and markets more than 500 sample and assay products as well as
automated solutions for such consumables. The company provides its products to
molecular diagnostics laboratories, academic researchers, pharmaceutical and
biotechnology companies, and applied testing customers for purposes such as
forensics, animal or food testing and pharmaceutical process control. QIAGEN's
assay technologies include one of the broadest panels of molecular diagnostic
tests available worldwide. This panel includes the digene HPV Test, which is
regarded as a "gold standard" in testing for high-risk types of human
papillomavirus (HPV), the primary cause of cervical cancer, as well as a broad
suite of solutions for infectious disease testing and companion diagnostics.
QIAGEN employs more than 3,500 people in over 30 locations worldwide. Further
information about QIAGEN can be found at

http://www.qiagen.com/.

Certain of the statements contained in this news release may be considered
forward-looking statements within the meaning of Section 27A of the U.S.
Securities Act of 1933, as amended, and Section 21E of the U.S. Securities
Exchange Act of 1934, as amended. To the extent that any of the statements
contained herein relating to QIAGEN's products, markets, strategy or operating
results are forward-looking, such statements are based on current expectations
that involve a number of uncertainties and risks. Such uncertainties and risks
include, but are not limited to, risks associated with management of growth and
international operations (including the effects of currency fluctuations and
risks of dependency on logistics), variability of operating results, the
commercial development of the applied testing markets, clinical research markets
and proteomics markets, nucleic acid-based molecular diagnostics market, and
genetic vaccination and gene therapy markets, competition, rapid or unexpected
changes in technologies, fluctuations in demand for QIAGEN's, products
(including fluctuations due to the level and timing of customers' funding,
budgets, and other factors), our ability to obtain regulatory approval of our
infectious disease panels, difficulties in successfully adapting QIAGEN's
products to integrated solutions and producing such products, the ability of
QIAGEN to identify and develop new products and to differentiate its products
from competitors' products, market acceptance of QIAGEN's new products and the
integration of acquired technologies and businesses. For further information,
refer to the discussions in reports that QIAGEN has filed with, or furnished to,
the U.S. Securities and Exchange Commission (SEC).

Contacts:

 Investor Relations:                  Public Relations:
 Dr. Solveigh Mähler                  Dr. Thomas Theuringer
 Director Investor Relations          Director Public Relations
 QIAGEN N.V.                          QIAGEN GmbH
 [phone]                    [phone]
 e-mail:[e-mail]   e-mail:[e-mail]

 Albert F. Fleury
 Investor Relations North America
 QIAGEN N.V.
 [phone]
 e-mail:[e-mail]





[HUG#1441807]



 --- End of Message --- 

Qiagen N.V.
Spoorstraat 50 KJ Venlo Netherlands


Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse;





This announcement is distributed by Thomson Reuters on behalf of 
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and 
    other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
     originality of the information contained therein. 
    
Source: Qiagen N.V. via Thomson Reuters ONE